What type of study is this?

This is a In Vitro Study study.

December 8, 2025BloodOpen Access

Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

YJYead JewelCity Of Hope National Medical Center HCHyeran ChoiCity Of Hope National Medical Center AKAmrita KrishnanCity Of Hope National Medical Center

Discussion

Member takes

Implication

Preclinical data reveal improved efficacy of novel antibody-drug conjugates targeting CD38 in multiple myeloma, implicating promising treatment avenues.

Key Points

Enhanced anti-MM efficacy was observed with novel antibody-drug conjugates targeting CD38, improving outcomes.
In vivo experiments showed significant anti-tumor effects using bioluminescence imaging of treated mice.
Monoclonal antibodies facilitate immune responses through natural killer cells and macrophages, highlighting their importance.
This research presents a significant advancement in developing targeted therapies for multiple myeloma with acquired resistance.

Cite This Study

Jewel et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db81 https://doi.org/10.1182/blood-2025-2161

View Full Paper

Ask AI

Bookmark

Implication

Preclinical data reveal improved efficacy of novel antibody-drug conjugates targeting CD38 in multiple myeloma, implicating promising treatment avenues.

Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider